Sixty percent of invasive disease cases in children are caused by the new strains
No Brasil, onde doenças pneumocócicas ainda ceifam vidas por pneumonia, meningite e sepse, a Anvisa aprovou em dezembro de 2023 a Prevenar 20, vacina da Pfizer capaz de proteger contra vinte cepas do pneumococo — sete a mais do que sua predecessora. A decisão representa um avanço concreto na prevenção de formas graves da doença, especialmente para crianças pequenas, idosos e pessoas com comorbidades, embora o acesso real dependa ainda do processo de regulação de preços que se desenrola nos próximos meses. É um daqueles momentos em que a ciência abre uma porta que a burocracia ainda precisa atravessar.
- Cerca de 60% dos casos de doença pneumocócica invasiva em crianças brasileiras são causados por cepas que só agora passam a ser cobertas por uma vacina aprovada no país.
- A aprovação pela Anvisa em 18 de dezembro de 2023 encerra uma etapa, mas abre outra: a Pfizer tem até noventa dias para obter da CMED um preço autorizado antes que o produto chegue às farmácias.
- Para idosos, a Prevenar 20 elimina a necessidade de duas doses sequenciais com vacinas diferentes, oferecendo proteção equivalente em uma única aplicação.
- A diretora da sociedade brasileira de imunizações projeta disponibilidade no mercado até o final do primeiro trimestre de 2024, seguindo o caminho já aberto pela aprovação do FDA nos Estados Unidos em abril do mesmo ano.
A Anvisa aprovou a Prevenar 20, vacina pneumocócica da Pfizer, em 18 de dezembro de 2023, abrindo caminho para uma proteção mais ampla contra uma bactéria capaz de causar pneumonia, meningite e infecções na corrente sanguínea. A novidade em relação à versão anterior está em sete cepas adicionais — a Prevenar 13 cobria treze; a nova cobre vinte. Esse acréscimo não é apenas numérico: dados de vigilância indicam que as três cepas mais relevantes entre as novas incluídas respondem por aproximadamente 60% dos casos de doença invasiva em crianças brasileiras.
Antes de chegar às clínicas e farmácias, a vacina precisa passar pela regulação de preços da CMED, que dispõe de noventa dias para deliberar. Flávia Bravo, diretora da sociedade de imunizações do país, estima que o produto esteja disponível até o fim do primeiro trimestre de 2024. A aprovação prévia pelo FDA americano, em abril de 2023, indica que o caminho regulatório já está bem estabelecido.
As populações-alvo são crianças menores de cinco anos, adultos acima de sessenta e pessoas de qualquer idade com condições que elevam o risco — como HIV, diabetes, obesidade ou transplante de órgãos. Para idosos, a Prevenar 20 traz uma vantagem prática imediata: substitui o esquema atual de duas doses com vacinas diferentes por uma única aplicação de proteção equivalente.
Os efeitos colaterais seguem o padrão das vacinas pneumocócicas — dor, inchaço e vermelhão no local da injeção, eventualmente febre — e se resolvem sem sequelas. A vacina não deve ser administrada a pessoas com histórico de reação alérgica grave a qualquer componente da fórmula ou ao toxoide diftérico. A aprovação amplia o arsenal preventivo do Brasil contra as formas mais graves da doença pneumocócica, mas sua real dimensão dependerá de como o processo de precificação se desenrolará nos próximos meses.
Brazil's health regulator has cleared a new pneumococcal vaccine that offers broader protection against a disease that can turn into pneumonia, meningitis, or bloodstream infection. The vaccine, called Prevenar 20 and made by Pfizer, received approval from Anvisa on Monday, December 18th, and now enters a pricing phase that will determine when it reaches pharmacies and clinics.
The vaccine targets 20 different strains of pneumococcus, the bacterium responsible for pneumococcal disease. Seven of those strains are new to this formulation—the previous version, Prevenar 13, covered only thirteen. This expansion matters concretely: according to current surveillance data, roughly 60 percent of invasive pneumococcal disease cases in Brazilian children are caused by the three most significant new strains included in Prevenar 20. The vaccine protects against strains labeled 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.
Before the vaccine can be sold, Pfizer must submit pricing information to Brazil's drug price regulation board, known as CMED. That board has ninety days to approve a price. Flávia Bravo, director of Brazil's immunization society, expects the vaccine to be available by the end of the first quarter of 2024. The United States approved Prevenar 20 in April of this year through the FDA, suggesting the regulatory pathway is well-established.
The vaccine is designed for specific populations. Children under five years old, adults sixty and older, and anyone of any age living with conditions that increase pneumococcal risk—HIV infection, diabetes, obesity, organ transplant status, among others—are the intended recipients. For people between five and fifty-nine without such conditions, the risk of severe disease is low enough that routine vaccination is not recommended. Bravo emphasized that the vaccine is licensed from six weeks of age onward and can be used in routine childhood and elderly immunization schedules as well as for patients with elevated risk.
For elderly patients, Prevenar 20 offers a practical advantage. Current practice requires two shots: first Prevenar 13, then later a 23-valent vaccine to fill gaps. Prevenar 20 accomplishes the same protection in a single dose, eliminating the need for sequential vaccination. The older 13-valent vaccine continues to serve well for the strains currently circulating in Brazil that cause the most severe disease, so it remains a viable option for many patients.
Side effects are typical for pneumococcal vaccines: pain at the injection site, swelling, redness, and sometimes fever. These symptoms resolve without lasting harm and can be managed with fever-reducing medication and a cold compress. The vaccine should not be given to anyone with a severe allergic reaction to any component of Prevenar 20 or to diphtheria toxoid.
Pneumococcal disease spreads person to person through respiratory droplets—the bacteria travel when someone coughs, sneezes, or speaks. The infection can remain mild, causing ear infections, or become life-threatening, causing pneumonia, meningitis, or sepsis. The approval of Prevenar 20 expands Brazil's ability to prevent the most dangerous forms of this disease, though actual availability will depend on how the price regulation process unfolds over the coming months.
Citações Notáveis
For elderly patients, Prevenar 20 eliminates the need for sequential vaccination—a single dose provides the protection that previously required two shots— Flávia Bravo, director of Brazil's immunization society
The three new strains in Prevenar 20 are critically important for Brazil, accounting for about 60% of invasive disease cases in children today— Flávia Bravo, director of Brazil's immunization society
A Conversa do Hearth Outra perspectiva sobre a história
Why does this vaccine matter now, in Brazil specifically? Hasn't pneumococcal disease been preventable for years?
Yes, but the older vaccines covered fewer strains. What's changed is that we now have data showing which strains are actually causing the most severe disease in Brazilian children and elderly people. Prevenar 20 covers seven additional strains that weren't in the previous version, and those seven account for a significant chunk of the invasive cases we're seeing.
When you say invasive cases, what does that mean?
Pneumonia, meningitis, bloodstream infection—the serious forms that can kill or disable someone. The disease can also cause ear infections, which are annoying but not dangerous. The vaccine is specifically designed to prevent the dangerous versions.
Who actually needs this vaccine? Is it for everyone?
No. Children under five, yes. Adults over sixty, yes. But for healthy people between five and sixty, the risk is low enough that routine vaccination isn't recommended. The vaccine is really for people with conditions that weaken their immune system or increase their risk—HIV, diabetes, obesity, transplant recipients. And it's licensed from six weeks of age, so it can be used in special cases even in infants.
What's the practical difference for an elderly person compared to the old vaccine?
The old approach required two shots—first one vaccine, then months later a second one to cover the gaps. With Prevenar 20, you get one shot and you're done. That's simpler, and people are more likely to actually complete a one-shot regimen than a two-shot one.
When will people actually be able to get it?
That depends on pricing. The regulatory board has ninety days from when Pfizer submits its price request to approve it. The director of Brazil's immunization society thinks it could be available by the end of the first quarter of 2024, but that's contingent on the price negotiation moving smoothly.